WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and ...
HanchorBio and WuXi Biologics collaborate to develop fusion proteins using the Fc-Based Designer Biologics platform, ...
WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and ...
News-Medical.Net on MSN
JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth
On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, ...
China-based biologics services group WuXi Biologics (HKG: 2269) has entered a strategic collaboration with Sinorda ...
WuXi Biologics and Sinorda Biomedicine have jointly announced a strategic collaboration for the development and manufacturing of SND006.
WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development and manufacturing of innovative bispecific antibody: Shanghai Friday, January 30, 2026, 10:00 Hrs [IST ...
WuXi Biologics says the company will provide the partnership with integrated, end-to-end biologics development and manufacturing services.
Press Trust of India on MSN
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
SHANGHAI, Jan ...
Taiwanese biotech HanchorBio (TPEx: 7827) has signed a strategic collaboration with WuXi Biologics (HKEX: 2269) to develop ...
This edition of the Belt and Road Monitor covers 1st to 31st December 2025 - China Russia and BRI project developments ...
Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results